ES2446494B1 - Therapeutic application of necrostatin-1 in steatohepatitis - Google Patents

Therapeutic application of necrostatin-1 in steatohepatitis Download PDF

Info

Publication number
ES2446494B1
ES2446494B1 ES201230461A ES201230461A ES2446494B1 ES 2446494 B1 ES2446494 B1 ES 2446494B1 ES 201230461 A ES201230461 A ES 201230461A ES 201230461 A ES201230461 A ES 201230461A ES 2446494 B1 ES2446494 B1 ES 2446494B1
Authority
ES
Spain
Prior art keywords
necrostatin
steatohepatitis
therapeutic application
alcoholic
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201230461A
Other languages
Spanish (es)
Other versions
ES2446494A1 (en
Inventor
José Carlos FERNÁNDEZ-CHECA TORRES
María Del Carmen GARCÍA RUIZ
Albert MORALES MUÑOZ
Anna COLELL RIERA
Monserrat MARI GARCÍA
Susana NÚÑEZ POZUELO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201230461A priority Critical patent/ES2446494B1/en
Publication of ES2446494A1 publication Critical patent/ES2446494A1/en
Application granted granted Critical
Publication of ES2446494B1 publication Critical patent/ES2446494B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Abstract

Aplicación terapéutica de necrostatina-1 en esteatohepatitis.#La presente invención se refiere al uso de necrostatina-1 para fabricar una composición farmacéutica para prevenir y/o tratar la esteatohepatitis tanto alcohólica (ASH) como no alcohólica (NASH). Así como, al uso de necrostatina-1 para fabricar una composición nutracéutica para prevenir la esteatohepatitis. Adicionalmente, la presente invención también hace referencia a un alimento funcional que comprende necrostatina-1 para prevenir la esteatohepatitis.Therapeutic application of necrostatin-1 in steatohepatitis. # The present invention relates to the use of necrostatin-1 to manufacture a pharmaceutical composition for preventing and / or treating both alcoholic (ASH) and non-alcoholic (NASH) steatohepatitis. As well as the use of necrostatin-1 to manufacture a nutraceutical composition to prevent steatohepatitis. Additionally, the present invention also refers to a functional food comprising necrostatin-1 to prevent steatohepatitis.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

Claims (1)



 imagen1image 1
ES201230461A 2012-03-28 2012-03-28 Therapeutic application of necrostatin-1 in steatohepatitis Expired - Fee Related ES2446494B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201230461A ES2446494B1 (en) 2012-03-28 2012-03-28 Therapeutic application of necrostatin-1 in steatohepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230461A ES2446494B1 (en) 2012-03-28 2012-03-28 Therapeutic application of necrostatin-1 in steatohepatitis

Publications (2)

Publication Number Publication Date
ES2446494A1 ES2446494A1 (en) 2014-03-07
ES2446494B1 true ES2446494B1 (en) 2015-03-16

Family

ID=50190906

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230461A Expired - Fee Related ES2446494B1 (en) 2012-03-28 2012-03-28 Therapeutic application of necrostatin-1 in steatohepatitis

Country Status (1)

Country Link
ES (1) ES2446494B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI638815B (en) 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 Heterocyclic amides as kinase inhibitors
WO2017140835A1 (en) * 2016-02-19 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118587A1 (en) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer

Also Published As

Publication number Publication date
ES2446494A1 (en) 2014-03-07

Similar Documents

Publication Publication Date Title
UY33396A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
BR112015022047A8 (en) use of a composition comprising nanoparticles containing a limo family drug and an albumin
CU20140141A7 (en) 2-ACETAMIDO-5-ARIL-1,2,4-SUBSTITUTED TRIAZOLONES
CL2012000620A1 (en) Pharmaceutical formulations of an anti cd-20 antibody; use of the formulation to treat disease or disorder that can be corrected by anti-cd20 antibody treatment.
CO6410279A2 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
DOP2014000260A (en) D-AMINO ACIDS COMPOUNDS FOR HEPATIC DISEASE
NI201200175A (en) BLADDER CANCER TREATMENT METHODS
ECSP10010548A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
CL2013001947A1 (en) Pharmaceutical composition comprising pioglitazone; use of pioglitazone to treat Alzheimer's; composition comprising pioglitazone.
CR20110466A (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
DOP2007000102A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONA SUBSTITUTED AS WELL AS ITS USE
CO6280490A2 (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE
DOP2007000043A (en) SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE
UY31765A (en) SUBSTITUTED DIHYDROPIRAZOLONAS AND ITS USE
UY32052A (en) 5-REPLACED AMINOPIRAZOLS AND USE OF THE SAME
BRPI0822069B8 (en) method for preparing a milk thistle fruit extract
CO7160080A2 (en) Lipid compositions of racecadot
DOP2010000400A (en) 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME
ES2446494B1 (en) Therapeutic application of necrostatin-1 in steatohepatitis
ECSP12011951A (en) USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR A PARASITARY DISEASE
CO7170180A2 (en) Injectable pharmaceutical composition of dexketoprofen and tramadol
BR112015023872A2 (en) composition comprising arabinogalactan and polyphenols of larch trees
PH12016501553A1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
NI201200162A (en) PIRAZOLIL QUINOXALINE KINASE INHIBITORS
CU20100260A7 (en) 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2446494

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150316

FD2A Announcement of lapse in spain

Effective date: 20210915